COTY
21.4.2021 10:02:12 CEST | Business Wire | Press release
Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies and the global leader in fragrances, today announced that Lancaster has become the first ever sun care brand awarded the prestigious C2C Certified Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210421005237/en/
The award indicates that 100% of the ingredients in Lancaster Sun Sensitive collection –Lancaster’s first clean and vegan range, and its most environmentally friendly yet - meet the Institute’s strict criteria. In addition to recognizing the sustainable innovation behind the collection, the Certification serves as the foundation for further improving the sustainability and product safety of sun care products over time.
Lancaster Sun Sensitive collection provides broad sun protection* targeting 100% of sun spectrum through a clean, minimalistic** vegan formula providing even sensitive skin with a delicate golden glow, preserved from redness and discomfort. The products also feature an ocean friendly UV filter system*** - all delivered in eco-designed packaging.****
Sue Y. Nabi, Chief Executive Officer at Coty , said: “Sustainability is the ultimate driver of innovation and brands like Lancaster are creating outstanding products that are truly clean and green. Today’s consumer rightly expects that their favorite products also deliver when it comes to environmental performance. It’s our approach to product innovation that sets Coty apart and these industry firsts reflect the expertise of our teams and our brands.”
The C2C Certified Material Health Certificate by the Cradle to Cradle Products Innovation Institute offers a solution to growing industry and consumer interest in knowing more about the chemicals used in products across their supply chains and avoiding chemicals of concern. By using the rigorous, globally recognized material health assessment methodology of the Cradle to Cradle Certified Product Standard, the Material Health Certificate provides manufacturers with a trusted means of assessing, optimizing and verifying their product chemistries for safety and the environment. A C2C Certified Material Health Certificate is awarded to products that meet the Material Health requirements of the multi-attribute Cradle to Cradle Certified™ Product Standard. The certificate is valid for two years.
“Beyond leading the way in sun care with the first C2C Certified Material Health Certificate in the category, Coty is also paving the way towards greater product safety, transparency and innovation throughout the beauty industry ,” said Dr. Christina Raab, Vice President of Strategy and Development for the Cradle to Cradle Products Innovation Institute.
Laure Calvel, VP Global Marketing at Lancaster , said: “Receiving the Cradle to Cradle Products Innovation Institute’s Silver Level Material Health Certificate for our Sun Sensitive range is another positive step in demonstrating the safe use of materials that are circular and responsible in our products. We have a framework for improving the sustainability of all the products in our portfolio and very ambitious plans over the coming years.”
Product innovation is a crucial element of Coty’s journey to becoming a more circular business and creating a more sustainable and inclusive world – as set out in its Beauty That Lasts’ strategy. Today’s announcement builds on the success of Calvin Klein’s first clean and environmentally conscious fragrance, CK EVERYONE, which achieved a Material Health Certificate at the Silver level from the Cradle to Cradle Products Innovation Institute in April 2020.
Last month, Coty announced a partnership with LanzaTech to introduce sustainable ethanol made from captured-carbon emissions into its fragrance products. LanzaTech captures industrial emissions and processes the waste gases into a new, more sustainable source of ethanol that is suitable for use in fragrances. Coty has set the goal of having the majority of its fragrance portfolio using ethanol sourced from carbon-capture by 2023.
* No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
** Formulas contain on average 40% fewer ingredients than previous range/competitors.
*** In vitro test method established with the University of Nice Institute to assess the potential impact of a sunscreen product on cnidarian cells.
**** Tubes/bottles contain at minimum 50% post-consumer recycled materials.
About Coty Inc.
Coty is one of the world’s largest beauty companies with an iconic portfolio of brands across fragrance, color cosmetics, and skin and body care. Coty is the global leader in fragrance and number three in color cosmetics. Coty’s products are sold in over 150 countries around the world. Coty and its brands are committed to a range of social causes as well as seeking to minimize its impact on the environment. For additional information about Coty Inc., please visit www.coty.com .
About the Cradle to Cradle Products Innovation Institute
The Cradle to Cradle Products Innovation Institute is dedicated to powering innovation for the circular economy through products that have a positive impact on people and planet. Through the Cradle to Cradle Certified® Products Program, the Institute sets the global standard for products that are safe, circular and made responsibly. Cradle to Cradle Certified is used by many future-focused designers, brands, retailers and manufacturers across the value chain to innovate and optimize materials and products according to the world’s most advanced science-based measures for material health, product circularity, renewable energy and climate, water and soil stewardship, and social fairness. The Institute also powers the global shift to a circular economy through partnerships and collaborative initiatives that equip businesses, governments and other stakeholders with the technical solutions and knowledge they need to innovate the way products are designed and made. For more information about the Institute, visit c2ccertified.org. C2C Certified Material Health Certificate™ is a word mark licensed by the Cradle to Cradle Products Innovation Institute.
About Lancaster SUN SENSITIVE
Lancaster’s broadest sun protection respects the most sensitive skin’s needs:
- Provides optimal protection with Full Light Technology, which targets 100% of sun spectrum (1) (UVB, UVA, Visible Light and Infrared rays).
- Gives a luminous and long-lasting tan which develops gradually thanks to the exclusive natural origin Tan Activator Complex, which stimulates the natural tanning process for a never-ending summer.
- Helps reduce redness and the feeling of discomfort while protecting sensitive skin from sun damage, thanks to the new natural origin Sunsicalm complex.
- Respects marine life, with an ocean friendly UV filter system and water-resistant formulas, while being respectful for the skin with minimalistic (2), vegan formulas, all in eco-designed packaging (3).
- Provides ultra-sensorial and lightweight textures yet clean, that penetrates easily without leaving white traces with a transparent finish after application and a clean labelled fragrance.
- For children, a convenient face and body spray that meets all their needs (anti-sand, wet skin application, tearless formula, water resistant and fragrance-free).
- No sunscreen product can provide full protection against sun’s rays. Overexposure to the sun is a dangerous health risk.
- Formulas contain on average 40% fewer ingredients than previous range/competitors.
- Tubes/bottles contain at minimum 50% post-consumer recycled materials.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005237/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
